脂肪性肝炎生物标志物与丙型肝炎消除后肝细胞癌的关联
本研究基于290例经直接抗病毒药物实现丙型肝炎病毒消除且无肝细胞癌病史的慢性丙型肝炎患者的前瞻性队列数据库,计算治疗结束后12周的FAST评分,分析肝细胞癌发生风险。中位随访4.2年,FAST评分≥0.35与肝细胞癌累积发生率显著升高相关,在肝硬度≥10 kPa患者中校正后风险比为4.41,多变量校正后FAST评分≥0.35与肝细胞癌发生相关(校正HR 4.42)。
要点
- FAST评分≥0.35者肝细胞癌累积发生率显著高于FAST评分<0.35者(log-rank检验P<0.001)。
- 肝硬度≥10 kPa患者中,FAST评分≥0.35者肝细胞癌年发生率显著高于FAST评分<0.35者(校正HR 4.41)。
- 多变量校正后,FAST评分≥0.35与肝细胞癌发生相关(校正HR 4.42,95%CI 1.02-19.9,P=0.043)。
核心结论
- 脂肪性肝炎相关生物标志物FAST评分有助于预测丙型肝炎病毒消除后肝细胞癌的发生。
研究设计与样本
- 本队列研究分析了290例无肝细胞癌病史、经直接抗病毒药物实现丙型肝炎病毒消除的慢性丙型肝炎患者的前瞻性数据库。
- 计算治疗结束后12周(pw12)的FibroScan-天冬氨酸氨基转移酶(FAST)评分。
- 采用多变量Cox比例风险模型分析肝细胞癌风险。
主要发现
- 丙型肝炎病毒基因1型最常见,占72.4%,其次为基因2型(26.6%)。
- 中位随访期为4.2年(IQR 3.1-4.5)。
- FAST评分≥0.35者的肝细胞癌累积发生率显著高于FAST评分<0.35者(log-rank检验P<0.001)。
- 在肝硬度测量≥10 kPa的患者中,FAST评分≥0.35者的肝细胞癌年发生率显著高于FAST评分<0.35者(校正HR 4.41,95%CI 1.30-15.0,P=0.018)。
- 校正年龄、白蛋白、甲胎蛋白、PNPLA3 rs738409基因型及pw12纤维化标志物(FIB-4、非酒精性脂肪性肝病纤维化评分和肝硬度测量)后,FAST评分≥0.35与肝细胞癌发生相关(校正HR 4.42,95%CI 1.02-19.9,P=0.043)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A strong association between chronic hepatitis C (CHC) and hepatic steatosis has been reported. However, the influence of steatohepatitis on hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) elimination remains unclear. AIM: To evaluate the development of HCC after HCV cure using a new steatohepatitis-related biomarker. METHODS: This cohort study analysed the prospective database of 290 CHC patients without a history of HCC who achieved HCV elimination by direct-acting antivirals. We calculated the FibroScan-aspartate aminotransferase (FAST) score 12 weeks after the end of treatment (pw12). The risk of HCC was analysed using the multivariable Cox proportional hazard model. RESULTS: HCV genotype (GT)1 was most prevalent at 72.4%, followed by GT2 (26.6%). Median follow-up period was 4.2 years (IQR 3.1-4.5). The cumulative HCC incidence for a FAST score ≥ 0.35 was significantly higher than that for a FAST score < 0.35 (log-rank test: P < 0.001). The annual HCC incidence rate for a FAST score ≥ 0.35 was significantly higher than that for a FAST score < 0.35, in patients with liver stiffness measurement (LSM) ≥10 kPa (adjusted hazard ratio [HR] 4.41, 95% confidence interval [CI] 1.30-15.0, P = 0.018). After adjusting for variables, including age, albumin, alpha-fetoprotein, the patatin-like phospholipase domain-containing the 3 (PNPLA3) rs738409 genotype, and pw12 fibrosis markers with FIB-4, non-alcoholic fatty liver disease fibrosis score, and LSM, FAST score ≥ 0.35 was associated with the development of HCC (adjusted HR 4.42, 95% CI 1.02-19.9, P = 0.043). CONCLUSIONS: Steatohepatitis-related biomarkers with the FAST score are helpful for predicting the development of HCC after HCV elimination.
引用
- Ogawa E, Takayama K, Hiramine S, et al. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Aliment Pharmacol Ther. 2020. PMID: 32697871. doi:10.1111/apt.15976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。